Back to top
more

Adverum Biotechnologies (ADVM)

(Delayed Data from NSDQ)

$6.70 USD

6.70
124,893

-0.02 (-0.30%)

Updated Aug 6, 2024 04:00 PM ET

After-Market: $6.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

by Zacks Equity Research

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

by Zacks Equity Research

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

Geron (GERN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.

Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

by Zacks Equity Research

Adverum Biotechnologies (ADVM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

by Zacks Equity Research

Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.

PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

PetIQ's (PETQ) first-quarter results are likely to reflect growth in the Product and Services segments of the business.

Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

by Zacks Equity Research

Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.

How Adverum (ADVM) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.